Bioventix plc
(“Bioventix” or
“the Company”)
Trading Update
& Notice of Results
Bioventix plc (BVXP), a UK company specialising in the
development and commercial supply of high-affinity monoclonal
antibodies for applications in clinical diagnostics, is pleased to
announce a trading update for the year ended 30 June 2022 (“FY2022”).
As announced in our interim results to 31
December 2021, we had a slow start to the financial year.
However, in the second half, we have seen an improvement in
performance and our trading result for FY2022 as a whole is likely
to be significantly ahead of market expectations.
This improvement reflects a degree of recovery from the pandemic
effects experienced since early 2020, and we hope that this
recovery will prove to be sustained and long-lasting. We are
pleased that the roll-out of high sensitivity troponin products,
that are supported by our technology, has also matched our
expectations.
In addition, our results are reported in UK Sterling and the
recent fall in value of the UK Sterling against the US Dollar has
had a positive effect. Approximately 50% of our revenues are linked
to US Dollars and royalties received recently from customers in
respect of our H2 sales have been converted at more favourable
exchange rates.
Notice of Results
Bioventix expects to release FY2022 results on 24 October 2022.
For further information please
contact:
Bioventix
plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks
Alice Lane |
Corporate Finance
ECM |
Tel: 020 7220 0500 |
This announcement contains inside
information for the purposes of Article 7 of the Market Abuse
Regulation (EU) 596/2014 as it forms part of UK domestic law by
virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the company's obligations under
Article 17 of MAR.